# Efficacy of Lapaquistat Acetate on Blood Cholesterol Levels in Treating Subjects With Hypercholesterolemia

> **NCT00532558** · PHASE3 · TERMINATED · sponsor: **Takeda** · enrollment: 657 (actual)

## Conditions studied

- Hypercholesterolemia

## Interventions

- **DRUG:** Lapaquistat acetate
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00532558
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-10
- **Primary completion:** 2008-05
- **Final completion:** 2008-05
- **Target enrollment:** 657 (ACTUAL)
- **Why stopped:** Overall profile of the compound does not offer significant clinical advantage to patients over currently available lipid lowering agents
- **Last updated:** 2012-05-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00532558

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00532558, "Efficacy of Lapaquistat Acetate on Blood Cholesterol Levels in Treating Subjects With Hypercholesterolemia". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00532558. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*